Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2000 May 4

PMID 10793082

Citations 67

Authors

L Lamant

K Pulford

D Bischof

S W Morris

D Y Mason

G Delsol

B Mariame

Affiliations

Soon will be listed here.

Abstract

ALK (anaplastic lymphoma kinase) is a tyrosine kinase receptor, expressed as part of the chimeric NPM-ALK protein, in anaplastic large cell lymphomas (ALCLs) exhibiting the t(2;5)(p23;q35) translocation. As a result of this translocation, the NPM (nucleophosmin) gene is fused to the portion of the ALK gene encoding its intracytoplasmic segment. In normal mouse tissues, mRNA encoding the Alk receptor has been found only in neural cells, suggesting involvement of this receptor in the development of the nervous system. The purpose of the present study was to examine the presence of ALK transcripts and protein in normal human tissues and a variety of cell lines and human tumors. Emphasis was placed on neuroblastomas because other tyrosine kinase receptors are expressed in human neuroblastomas. Fifty-six cell lines, including 29 lines of neural origin, and lymphoid and nonlymphoid tissue specimens, including 24 neuroblastomas, were investigated for ALK expression, using reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry. The results confirmed that mRNA encoding ALK protein was not detectable in any normal or neoplastic hematopoietic tissue tested, except for t(2;5)-positive ALCL. The salient finding was that 13 of the 29 cell lines of neural origin and 22 of 24 neuroblastomas were found to express ALK transcripts and ALK protein. However, no correlation was evident between any known prognostic factors and the level of ALK expression.

Citing Articles

Lysophosphatidic Acid Stimulates Mitogenic Activity and Signaling in Human Neuroblastoma Cells through a Crosstalk with Anaplastic Lymphoma Kinase.

Dedoni S, Olianas M, Onali P Biomolecules. 2024; 14(6).

PMID: 38927035 PMC: 11201523. DOI: 10.3390/biom14060631.

Comparison of Lu-octreotate and Lu-octreotide for treatment in human neuroblastoma-bearing mice.

Romiani A, Simonsson K, Pettersson D, Al-Awar A, Rassol N, Bakr H Heliyon. 2024; 10(10):e31409.

PMID: 38826727 PMC: 11141386. DOI: 10.1016/j.heliyon.2024.e31409.

Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy.

Chen C, Sun Z, Wang Z, Shin S, Berrios A, Mellors J Antibodies (Basel). 2024; 13(2).

PMID: 38804307 PMC: 11130946. DOI: 10.3390/antib13020039.

Anaplastic Lymphoma Kinase (ALK) in Posterior Cranial Fossa Tumors: A Scoping Review of Diagnostic, Prognostic, and Therapeutic Perspectives.

Mousa D, Mavrovounis G, Argyropoulos D, Stranjalis G, Kalamatianos T Cancers (Basel). 2024; 16(3).

PMID: 38339401 PMC: 10854950. DOI: 10.3390/cancers16030650.

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.

Bergaggio E, Tai W, Aroldi A, Mecca C, Landoni E, Nuesch M Cancer Cell. 2023; 41(12):2100-2116.e10.

PMID: 38039964 PMC: 10793157. DOI: 10.1016/j.ccell.2023.11.004.

References

Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri S, Delsol G . ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998; 153(3):875-86. PMC: 1853018. DOI: 10.1016/S0002-9440(10)65629-5. View

Mason D, Pulford K, Bischof D, Kuefer M, Butler L, Lamant L . Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res. 1998; 58(5):1057-62. View

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Borer R, Lehner C, Eppenberger H, Nigg E . Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989; 56(3):379-90. DOI: 10.1016/0092-8674(89)90241-9. View

Nakagawara A, Arima M, Azar C, Scavarda N, Brodeur G . Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 1992; 52(5):1364-8. View

Borrello M, Bongarzone I, Pierotti M, Luksch R, Gasparini M, Collini P . trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages. Int J Cancer. 1993; 54(4):540-5. DOI: 10.1002/ijc.2910540404. View

Matsushima H, BOGENMANN E . Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo. Mol Cell Biol. 1993; 13(12):7447-56. PMC: 364816. DOI: 10.1128/mcb.13.12.7447-7456.1993. View

Morris S, Kirstein M, Valentine M, Dittmer K, Shapiro D, Saltman D . Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263(5151):1281-4. DOI: 10.1126/science.8122112. View

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

10.

Lahti J, Valentine M, Xiang J, Jones B, Amann J, Grenet J . Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. Nat Genet. 1994; 7(3):370-5. DOI: 10.1038/ng0794-370. View

11.

Shiota M, Fujimoto J, Takenaga M, Satoh H, Ichinohasama R, Abe M . Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood. 1994; 84(11):3648-52. View

12.

Rabbitts T . Chromosomal translocations in human cancer. Nature. 1994; 372(6502):143-9. DOI: 10.1038/372143a0. View

13.

Lamant L, Meggetto F, Al Saati T, Brugieres L, de Paillerets B, Dastugue N . High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood. 1996; 87(1):284-91. View

14.

Fujimoto J, Shiota M, IWAHARA T, Seki N, Satoh H, Mori S . Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A. 1996; 93(9):4181-6. PMC: 39508. DOI: 10.1073/pnas.93.9.4181. View

15.

Pahlman S, Hoehner J . Neurotrophin receptors, tumor progression and tumor maturation. Mol Med Today. 1996; 2(10):432-8. DOI: 10.1016/1357-4310(96)84847-7. View

16.

IWAHARA T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T . Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997; 14(4):439-49. DOI: 10.1038/sj.onc.1200849. View

17.

Pulford K, Lamant L, Morris S, Butler L, Wood K, Stroud D . Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997; 89(4):1394-404. View

18.

Brodeur G, Nakagawara A, Yamashiro D, Ikegaki N, Liu X, Azar C . Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol. 1997; 31(1-2):49-55. DOI: 10.1023/a:1005729329526. View

19.

Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P . A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood. 1997; 89(5):1483-90. View

20.

Bischof D, Pulford K, Mason D, Morris S . Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997; 17(4):2312-25. PMC: 232080. DOI: 10.1128/MCB.17.4.2312. View